Research

*September 2020* Note: this is in context of HER2, another resistance mechanism of EGFR TKIs. Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi. According to data from the phase 2 DESTINY-Lung01 trial, trastuzumab deruxtecan induced a confirmed objective response rate of…

*September 2020* The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses, conclude investigators of the pivotal trial that led to the drug's approval. Responses were seen in all patients regardless of how many previous drugs…

*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC). A third of patients with NSCLC had objective responses with sotorasib, and 88.1% attained disease control. The disease control rate (DCR) surpassed 90% in…

*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance mutations to standard EGFR-targeted therapies, including the third-generation EGFR TKI osimertinib (Tagrisso). Specifically, BLU-945 inhibited triple-mutant EGFR with sub-nanomolar potency and it also showed a greater than 900-fold selectivity over…

*September 2020* The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone. Read more.

*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1 CHRYSALIS study that were presented during the 2020 ESMO Virtual Congress.…

*September 2020* Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival. Read more.

*September 2020* Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical Oncology Program at the Taussig Cancer Institute of Cleveland Clinic, discusses the evolution of targeting HER2 in lung cancer. Watch the video.

*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment for patient with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor a MET exon 14 (METex14) skipping mutation identified via an FDA-approved test.1 The NDA is based on data from the…

*August 2020* The FDA has granted Priority Review to the New Drug Application (NDA) for trilaciclib (G1T28) for the treatment of patients with small cell lung cancer (SCLC) who are receiving chemotherapy, G1 Therapeutics announced in a press release. The Prescription Drug User Fee Act has an action date of…